Multiinstitutional prospective interventional study of biomarkers to predict efficacy and prognosis after nivolumab in patients with previously treated advanced renal cell carcinoma.
Not Applicable
Recruiting
- Conditions
- Advanced renal cell carcinoma patients who need secondary or tertiary therapy
- Registration Number
- JPRN-UMIN000030400
- Lead Sponsor
- Kobe University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who have been administered immune checkpoint inhibitors including nivolumab in the past Patients who have a history of malignant tumors other than renal cell carcinoma and are judged not to be cured Patients who are merging psychiatric symptoms or psychiatric disorders and considered difficult to participate in the study Patients decided not applicable for this study by physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What biomarkers correlate with nivolumab efficacy in previously treated advanced renal cell carcinoma (RCC) per JPRN-UMIN000030400?
How does PD-1 inhibition with nivolumab compare to VEGF-targeted therapies in secondary/tertiary advanced RCC treatment?
Which molecular pathways or immune markers predict prognosis after nivolumab in JPRN-UMIN000030400 multiinstitutional trial?
What are the immune-related adverse event profiles and management strategies for nivolumab in advanced RCC patients?
How do biomarkers from JPRN-UMIN000030400 inform combination therapies for PD-1-resistant advanced renal cell carcinoma?